Clinical Trials Logo

Blood Loss, Surgical clinical trials

View clinical trials related to Blood Loss, Surgical.

Filter by:

NCT ID: NCT03160170 Terminated - Surgical Blood Loss Clinical Trials

Efficacy of Suction Enabled Retraction Device

Start date: June 20, 2017
Phase: N/A
Study type: Interventional

This is a prospective randomized controlled trial of the Suction-Integrated Surgical Tissue Elevator & Retractor [SISTER] device to assess: - Effects on operative time and efficiency of exposure in open lumbar spine cases. - Effect on total blood loss during the exposure part of the operation. - Rate of clogging of suction device.

NCT ID: NCT03152461 Completed - Clinical trials for Blood Loss, Surgical

Evaluation of the Clinical Performance of the Quantra System With the Quantra Surgical Cartridge

Start date: May 23, 2017
Phase:
Study type: Observational

This study will evaluate the performance of the Quantra System comprised of the Quantra Hemostasis Analyzer with the Quantra Surgical Cartridge in patients undergoing major surgical procedures specifically, major cardiac and vascular procedures and major orthopedic surgery (primarily complex spine surgeries).

NCT ID: NCT03136952 Completed - Clinical trials for Anesthesia Complication

Cerebral Oxygenation, Different Measurement Points and Their Correlation in Pediatric Population

Start date: April 28, 2017
Phase:
Study type: Observational

Children who undergo surgery routinely for surgery that risk high levels of circulatory changes (eg heart surgery) is currently used routinely monitoring as regional oxygenation technology of the brain (NIRS). Near infrared spectroscopy (NIRS) is a technique for measuring regional oxygen saturation, indirect autoregulation of brain. We know that reduced oxygenation of the brain can occur with severe immediate blood loss. We in the research group has been able to note that in children who undergo surgery for cranioplasty interventions <1 year old, when they have ongoing excessive bleeding, decreases oxygenation in the brain and sometimes sharply before we can replace the loss of blood, even the blood pressure can be adequately maintained. Perioperative hypovolemia is a risk factor upset autoregulation of brain. Respect of which the mean arterial pressure (MAP) required to maintain intact autoregulation during general anesthesia still lacks a scientific consensus. By illuminating the skin and underlying tissue with infrared light in the spectra of 700 to 1100nm, it is possible to measure regional oxygen saturation in various tissues. At cerebral measuring sensor is placed frontally, just below the hairline. INVOS then returns the absolute values of cerebral oxygen saturation frontally in the area where the sensor is placed. A frontal placement may in some cases be impractical / impossible and thus limits the ability to monitor the brains of children with different types of surgery or body positions. At certain cranioplastic intervention surgery a frontal placement is not always possible, partly because of surgical technic reasons, but also that the child may have to lie prone during surgery. An alternative placement of INVOS sensor could mean greater opportunities to monitor cerebral oxygen saturation and thus increase patient safety within the mentioned categories of patients. An occipital location is practically possible in many cases. The purpose of this study is to investigate whether a occipital located sensor can measure cerebral oxygen saturation in a reliable manner.

NCT ID: NCT03122782 Not yet recruiting - Surgical Blood Loss Clinical Trials

Hemostatic Effect of Intrauterine Instillation Of Tranexamic Acid In Hysteroscopic Myomectomy

Start date: August 1, 2017
Phase: Phase 3
Study type: Interventional

Study Design: Randomized Controlled Clinical Trial. Study Population: The study population will be a consecutive series of participants attending the Early Cancer Detection Unit (ECDU) at Ain Shams University Maternity Hospital. 80 women who are scheduled to undergo a hysteroscopic myomectomy will be included and will be randomized into two groups: Group A: women will undergo a hysteroscopic myomectomy with the use of (TXA) Kapron in the distention medium Group B: women will undergo hysteroscopic myomectomy with the use of placebo(normal saline in the distention medium). Randomization will be performed using a Computer-generated randomization system. The allocated groups will be concealed in serially-numbered sealed opaque envelopes that will only be opened after recruitment. Patient allocation will be performed prior to the induction of anesthesia by an independent person, who will not otherwise be involved in this study. The trial will be appropriately blinded; the participants, outcome assessors and the surgeon performing the procedure will be blinded to the medication type, which will be used inside the distention medium. Therefore, this study will be a randomized double blind prospective clinical Methodology: 1. Informed written consent obtained from the participant. 2. History 1. Personal history 2. Menstrual history 3. Detailed obstetric history 4. Surgical intervention especially uterine surgeries and any post-operative complication 5. History of drug intake, especially hormonal treatment or anticoagulant therapy. 3. Routine preoperative investigations in addition to a serum pregnancy test if pregnancy is suspected. 4. Physical examination including general, abdominal and pelvic examination. 5. Hysteroscopy will be performed in the early proliferative phase using normal saline as a distention medium. 6. Only in intervention group (TXA group) KAPRON (Tranexamic acid) will be added to the injected media. - In intervention group 500 mg of Kapron for every 500 ml of distending media will be added. - In the control group, placebo .i.e. ,normal saline in the same form will be injected inside every 500 ml of the distention medium. 7. The trial will be appropriately blinded; the participants, outcome assessors and the surgeon performing the procedure will be blinded to the medication type, which will be used inside the distention medium. Therefore, our study will be a randomized double blind prospective clinical trial. 8. Intraoperative bleeding and quality of view will be observed. 9. A blood sample will be taken from each participant in both groups after 24 hours from the end of the operation for both hemoglobin and hematocrit levels. Types of outcome measures: Primary outcome measures: Estimated Blood loss defined as comparing the hematocrit and hemoglobin at base line (preoperative ) and 24 hours after surgery with the Tranexamic acid compared to the control group. Secondary outcome measures: The quality of view, duration of surgery, the volume of injected media, intraoperative complications and the success of the completion of the operation will be secondary outcomes.

NCT ID: NCT03112135 Recruiting - Clinical trials for Intraoperative Bleeding

Effect of Topical and Systemic Tranexemic Acid on Bleeding During Ear Exploration Surgery

Start date: April 2017
Phase: Phase 2
Study type: Interventional

The effect of tranexamic acid (TXA) on bleeding and improvement of surgical field during ear exploration surgery is not clear yet. This study will conducted to answer this question.

NCT ID: NCT03085394 Terminated - Tranexamic Acid Clinical Trials

Preoperative Hexakapron Reduces Bleeding in Bariatric Surgery

PHORBBS
Start date: September 1, 2017
Phase: Phase 3
Study type: Interventional

Prophylactic use of tranexamic acid to reduce intra and postoperative bleeding in primary sleeve gastrectomy procedures will be studied.

NCT ID: NCT03064568 Recruiting - Clinical trials for Myomectomy; Surgical Blood Loss

Rectal Misoprostol as a Hemostatic Agent During Abdominal Myomectomy

Start date: October 14, 2016
Phase: Phase 4
Study type: Interventional

Purpose is to identify if misoprostol in addition to local vasopressin decreases blood loss when compared to vasopressin alone, which is our current practice at this time. The study will be double-blinded with neither the patient nor the researcher knowing whether the placebo or the misoprostol was given. We will monitor patients for decrease in hemoglobin and hematocrit, need for transfusion, and operative time among other measures of perioperative morbidity to see if the addition of misoprostol makes a significant difference. We will also observe patients to see if there are any side effects of misoprostol that make its use undesirable.

NCT ID: NCT03047070 Completed - Clinical trials for Intraoperative Bleeding

Lidocaine in ERAS for FESS

Start date: February 9, 2017
Phase: Phase 2
Study type: Interventional

Functional endoscopic sinus surgery (FESS) is a commonly performed procedure. It is known that bleeding during FESS can affect directly to the visibility of safe landmarks and surgical outcomes.

NCT ID: NCT03044041 Completed - Clinical trials for Blood Loss, Surgical

Comparison Between Low Dose and High Dose Intra-articular Tranexamic Acid in Total Knee Arthroplasty

Start date: January 2016
Phase: Phase 4
Study type: Interventional

The purpose of this study is to compare blood loss between using low dose (500 mg) and high dose (3 g) topical intra-articular tranexamic acid after total knee arthroplasty in double-blind RCT

NCT ID: NCT03037515 Completed - Clinical trials for Blood Loss, Surgical

Oral and Intravenous Tranexamic Acid in Lumbar Spine Surgery

Start date: February 15, 2017
Phase: Phase 4
Study type: Interventional

The purpose of this project is to compare the effectiveness of two different but well accepted routes of administration of tranexamic acid in order to reduce blood loss and need for transfusion in patients undergoing lumbar spine surgery. Specifically, this study seeks to identify if intravenous tranexamic acid is superior to oral tranexamic acid in reducing blood loss and need for transfusion.